Scientists test CRISPR gene editing to fight sickle cell pain
NCT ID NCT04443907
Summary
This early-stage study tested a new gene-editing treatment for people with severe sickle cell disease. Doctors collected patients' own blood stem cells, used CRISPR technology to edit a gene to boost protective fetal hemoglobin, and then transplanted the cells back after chemotherapy. The main goals were to check if the treatment was safe and if it successfully increased fetal hemoglobin levels to reduce disease complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Ctr
New York, New York, 10065, United States
-
St Jude Children's Research Hospital
Memphis, Tennessee, 38105-3678, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.